Navigating Pediatric Inflammatory Skin Conditions in Skin of Color
At the most recent Skin of Color Update, we had the honor to learn about pediatric inflammatory skin conditions from the renowned Dr. Candrice Heath, triple board-certified dermatologist and Associate Professor at the Howard University Department of Dermatology and Dr. Brandi Kenner-Bell, Assistant Professor of Dermatology and Pediatrics at the Northwestern University Feinberg School of Medicine.
…
At the most recent Skin of Color Update, we had the honor to learn about pediatric inflammatory skin conditions from the renowned Dr. Candrice Heath, triple board-certified dermatologist and Associate Professor at the Howard University Department of Dermatology and Dr. Brandi Kenner-Bell, Assistant Professor of Dermatology and Pediatrics at the Northwestern University Feinberg School of Medicine.
… Continue reading "Navigating Pediatric Inflammatory Skin Conditions in Skin of Color"
People with skin of color are projected to become the majority of the U.S. population by 2044. As the population diversifies, how can dermatology clinicians better understand the dermatologic concerns of people with darker skin tones? A study published in the April Journal of Drugs in Dermatology sheds light on the most common reasons why patients of color seek outpatient dermatologic care, and th … 
Dermatology clinicians who treat inflammatory skin conditions in patients with skin of color should have a keen eye. Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Brandi Kenner-Bell, assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine. Watch as Dr. Kenner-Bell shares what to look for when diagnosing inflammatory s … 
This month’s Journal of Drugs in Dermatology issue is packed with groundbreaking studies and real-world insights spanning across age groups, skin types, and therapeutic categories. From improving dermatoporosis in older adults to exploring an acne management algorithm that smartly integrates acneceuticals, the April Editor’s Picks reflect dermatology’s evolving landscape.
Highlights include … 
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a … 